SCHEMBL366844

SCHEMBL366844

CCCCCNS(=O)(=O)c1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.79
PKM P14618 3/20 0.79
LMNA P02545 2/20 0.79
KDM4E B2RXH2 1/20 0.79
SMN1; SMN2 Q16637 1/20 0.79
TSHR P16473 1/20 0.73
EPHX2 P34913 1/20 0.66
MAPK1 P28482 2/20 0.65
TBXA2R P21731 2/20 0.63
CA12 O43570 2/20 0.60
CA9 Q16790 2/20 0.60
RECQL P46063 1/20 0.59
HTT P42858 1/20 0.55
NPSR1 Q6W5P4 1/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL578633 0.98 ALDH1A1 (0.82) ALDH1A1PKMLMNAKDM4ESMN1; SMN2
SCHEMBL578728 0.98 ALDH1A1 (0.82) ALDH1A1PKMLMNAKDM4ESMN1; SMN2
SCHEMBL579136 0.98 ALDH1A1 (0.82) ALDH1A1PKMLMNAKDM4ESMN1; SMN2
SCHEMBL633906 0.98 ALDH1A1 (0.82) ALDH1A1PKMLMNAKDM4ESMN1; SMN2
SCHEMBL5020960 0.98 ALDH1A1 (0.82) ALDH1A1PKMLMNAKDM4ESMN1; SMN2
SCHEMBL578832 0.98 ALDH1A1 (0.82) ALDH1A1PKMLMNAKDM4ESMN1; SMN2
SCHEMBL1279062 0.98 ALDH1A1 (0.82) ALDH1A1PKMLMNAKDM4ESMN1; SMN2
SCHEMBL51729 0.94 ALDH1A1 (0.76) ALDH1A1PKMLMNAKDM4ESMN1; SMN2
SCHEMBL27712513 0.94 ALDH1A1 (0.76) ALDH1A1PKMLMNAKDM4ESMN1; SMN2
Bicarbonate SCHEMBL9492528 0.93 ALDH1A1 (0.74) ALDH1A1PKMLMNAKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107778239-A A kind of synthetic method of phenanthridines and its derivative 浙江工业大学 2018-03-09 CN claimed
US-9790321-B2 Heat resistant polyethylene terephthalate and a process for the preparation of the same ESTER INDUSTRIES LIMITED (IN) 2017-10-17 US claimed
US-20160168321-A1 HEAT RESISTANT POLYETHYLENE TEREPHTHALATE AND A PROCESS FOR THE PREPARATION OF THE SAME ESTER INDUSTRIES LIMITED (IN) 2016-06-16 US claimed
EP-2999733-A1 HEAT RESISTANT POLYETHYLENE TEREPHTHALATE AND A PROCESS FOR THE PREPARATION OF THE SAME Ester Industries Limited (IN) 2016-03-30 EP claimed
CN-101111240-B Isolation of n-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of n-butylbenzenesulfonamide and benzenesulfonamide derivatives for the treatment of benign prostate hyperp LOHMANN THERAPIE SYST LTS 2011-09-21 CN claimed
US-7956216-B2 Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2011-06-07 US claimed
US-7700654-B2 Isolation of N-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of N-butylbenzenesulfonamide and benzenesulfonamide derivatives for treating benign prostatic hyperplasia and/or prostate carcinoma LTS LOHMANN THERAPIE-SYSTEME AG (DE) 2010-04-20 US claimed
US-20080153802-A1 Alpha-helical mimetics THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2008-06-26 US claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
EP-1763509-A1 ALPHA-HELICAL MIMETICS THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2007-03-21 EP claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
WO-2006002474-A1 ALPHA-HELICAL MIMETICS THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2006-01-12 WO claimed
CN-118439980-B Synthesis method of alpha-cyano sulfonamide derivative 浙江工业大学 2025-04-08 CN disclosed
CN-118439980-A Synthesis method of alpha-cyano sulfonamide derivative 浙江工业大学 2024-08-06 CN disclosed
US-11815815-B2 Composition for forming silicon-containing resist underlayer film removable by wet process NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2023-11-14 US disclosed
US-20220187709-A1 FILM-FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2022-06-16 US disclosed
EP-0068968-A1 Medicines containing as active ingredients compounds of the arylbenzenesulfonamide-type, and processes for their preparation CHOAY S.A. (FR) 1983-01-05 EP disclosed
US-4123411-A Plasticized composition of copolyetherester elastomer and aromatic sulfonamide MONSANTO COMPANY (US) 1978-10-31 US disclosed
US-4053458-A INHIBITORS UOP INC. (US) 1977-10-11 US disclosed
US-4022828-A BIS-(SULFONAMIDO)-SULFIDES UNIVERSAL OIL PRODUCTS COMPANY (US) 1977-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153802-A1 Alpha-helical mimetics BID, BAX, BAD ALDH1A1 4208/4885PKM 3582/4885LMNA 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.